Search

Your search keyword '"Stepanishyna, Yana"' showing total 25 results
Start Over Author "Stepanishyna, Yana"
25 results on '"Stepanishyna, Yana"'

1. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Author

Hapgood, Greg, Civallero, Monica, Stepanishyna, Yana, Vose, Julie, Cabrera, Monica Elena, Advani, Ranjana H., Pileri, Stefano A., Manni, Martina, Horwitz, Steven M., Foss, Francine M., Hitz, Felicitas, Radford, John, Dlouhy, Ivan, Chiattone, Carlos, Kim, Won Seog, Skrypets, Tetiana, Nagler, Arnon, Trotman, Judith, Luminari, Stefano, and Federico, Massimo

Published
2023
Full Text
View/download PDF

3. Reply to T. Vassilakopoulos et al

Author

Federico, Massimo, primary, Plattel, Wouter, additional, Hutchings, Martin, additional, Stepanishyna, Yana, additional, Fortpied, Catherine, additional, and André, Marc, additional

Published
2024
Full Text
View/download PDF

4. Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021

Author

Stepanishyna, Yana, primary, Manni, Martina, additional, Civallero, Monica, additional, Shokun, Nazar, additional, Skrypets, Tetiana, additional, Burtna, Alevtyna, additional, Shapovalenko, Natalia, additional, Tytorenko, Iryna, additional, Aleksyk, Olena, additional, Pastushenko, Yan, additional, Gubareva, Hanna, additional, Moiseienko, Kateryna, additional, Kadnikova, Tetyana, additional, Rudyuk, Timur, additional, Filonenko, Kateryna, additional, Martynchyk, Arina, additional, Novosad, Olga, additional, Galli, Giulia R., additional, Kryachok, Irina, additional, and Federico, Massimo, additional

Published
2024
Full Text
View/download PDF

5. PET/CT Imaging of Lymphoma Outside the Western World

Author

Gabus, Raoul, primary, Pavlovsky, Astrid, additional, Eleta, Martin, additional, Skrypets, Tetiana, additional, Kryachok, Irina, additional, Novosad, Olga, additional, Stepanishyna, Yana, additional, Kmetyuk, Yaroslav, additional, Alaskar, Ahmed, additional, Shaheen, Naila, additional, Ali, SA, additional, Al-Mansour, Mubarak, additional, Bergesio, Fabrizio, additional, and Chauvie, Stephane, additional

Published
2021
Full Text
View/download PDF

6. Long‐term outcome of peripheral T‐cell lymphomas: Ten‐year follow‐up of the International Prospective T‐cell Project.

Author

Civallero, Monica, Schroers‐Martin, Joseph G., Horwitz, Steven, Manni, Martina, Stepanishyna, Yana, Cabrera, Maria Elena, Vose, Julie, Spina, Michele, Hitz, Felicitas, Nagler, Arnon, Montoto, Silvia, Chiattone, Carlos, Skrypets, Tetiana, Perez Saenz, M. Angeles, Priolo, Giorgio, Luminari, Stefano, Lymboussaki, Athina, Pavlovsky, Astrid, Marino, Dario, and Liberati, Marina

Subjects
T cells, T-cell lymphoma, LYMPHOMAS, PATIENT experience, THERAPEUTICS
Abstract

Summary: Peripheral T‐cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long‐term outcomes. The International T‐cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long‐term outcome analysis on patients from the ITCLP with available 10‐year follow‐up data (n = 735). The overall response rate to first‐line therapy was 68%, while 5‐ and 10‐year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5‐ to 10‐year period (67%). Low‐risk International Prognostic Index and Prognostic Index for T‐cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2–4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front‐line therapeutic approaches in PTCLs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma

Author

Federico, Massimo, primary, Fortpied, Catherine, additional, Stepanishyna, Yana, additional, Gotti, Manuel, additional, van der Maazen, Richard, additional, Cristinelli, Caterina, additional, Re, Alessandro, additional, Plattel, Wouter, additional, Lazarovici, Julien, additional, Merli, Francesco, additional, Specht, Lena, additional, Schiano de Colella, Jean-Marc, additional, Hutchings, Martin, additional, Versari, Annibale, additional, Edeline, Véronique, additional, Stamatoulas, Aspasia, additional, Girinsky, Theodore, additional, Ricardi, Umberto, additional, Aleman, Berthe, additional, Meulemans, Bart, additional, Tonino, Sanne, additional, Raemaekers, John, additional, and André, Marc, additional

Published
2023
Full Text
View/download PDF

11. PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.

Author

Novosad, Olga, primary, Kriachok, Irina, additional, Rudiuk, Tymur, additional, Pastushenko, Ian, additional, Tytorenko, Iryna, additional, Aleksik, Olena, additional, Shudrak, Natalia, additional, Kadnikova, Tetiana, additional, Horbach, Olexandr, additional, Melnyk, Ulyana, additional, Mykhalska, Larysa, additional, Stepanishyna, Yana, additional, and Shokun, Nazar, additional

Published
2023
Full Text
View/download PDF

12. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Author

Federico, Massimo, Fortpied, Catherine, Stepanishyna, Yana, Gotti, Manuel, van der Maazen, Richard, Cristinelli, Caterina, Re, Alessandro, Plattel, Wouter, Lazarovici, Julien, Merli, Francesco, Specht, Lena, Schiano de Colella, Jean-Marc, Hutchings, Martin, Versari, Annibale, Edeline, Véronique, Stamatoulas, Aspasia, Girinsky, Theodore, Ricardi, Umberto, Aleman, Berthe, and Meulemans, Bart

Published
2024
Full Text
View/download PDF

14. Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Author

Hapgood, Greg, primary, Civallero, Monica, additional, Stepanishyna, Yana, additional, Vose, Julie M., additional, Cabrera, Maria Elena, additional, Advani, Ranjana H., additional, Pileri, Stefano A, additional, Manni, Martina, additional, Horwitz, Steven M., additional, Foss, Francine M., additional, Hitz, Felicitas, additional, Radford, John, additional, Dlouhy, Ivan, additional, Chiattone, Carlos S., additional, Kim, Won-Seog, additional, Skrypets, Tetiana, additional, Nagler, Arnon, additional, Trotman, Judith, additional, Luminari, Stefano, additional, and Federico, Massimo, additional

Published
2022
Full Text
View/download PDF

16. Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project

Author

Chiattone, Carlos, primary, Civallero, Monica, additional, Fischer, Thais, additional, Miranda, Eliana, additional, Manni, Martina, additional, Zing, Natalia P. C., additional, Pileri, Stefano A., additional, Montoto, Silvia, additional, Horwitz, Steven M., additional, Cabrera, Maria Elena, additional, De Souza, Carmino A., additional, Nagler, Arnon, additional, Luminari, Stefano, additional, Ferreri, Andrés J. M., additional, Carson, Kenneth R., additional, Re, Alessandro, additional, Rigacci, Luigi, additional, Nassi, Luca, additional, Stepanishyna, Yana, additional, Federico, Massimo, additional, and Inghirami, Giorgio, additional

Published
2022
Full Text
View/download PDF

18. Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.

Author

Kriachok, Iryna, Stepanishyna, Yana, Skrypets, Tetiana, Shokun, Nazar, Martynchyk, Arina, Tytorenko, Iryna, Aleksik, Olena, Krotevych, Mykhailo, Manni, Martina, and Federico, Massimo

Subjects
LYMPHOMAS, CANCER treatment, CLASSIFICATION, ACQUISITION of data
Abstract

The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma in Ukraine. Between September 2019 and October 2021, 546 patients with newly diagnosed lymphoma were prospectively registered. All cases were diagnosed according to the 2016 updated WHO lymphoma classification. The male‐to‐female ratio (M/F) for the whole population was 0.7, with a median age of 46 years (range 18–95). The adoption of the 2016 WHO classification resulted in the identification of 36 different lymphoma subtypes, with 132 cases (24.2%) classified differently compared to the 2008 WHO classification. Only 12 cases (2.8%) were true new entities, including seven cases of high‐grade B‐cell lymphoma NOS, three of anaplastic large B‐cell lymphoma, ALK‐negative, 1 case of HHV8+ DLBCL NOS, and 1 of high‐grade B‐cell lymphoma with C‐MYC and BCL2/BCL6 rearrangement. Moreover, 55 (61.1%) entities, including 37 defined by WHO 2008 and 18 defined by WHO 2016, were not represented at all. The analysis of cases registered in the ULR provides a comprehensive breakdown of the subtypes, stage distribution, and treatment of malignant lymphomas (ML) in Ukraine, supporting the usefulness of prospective data collection and timely reporting. We believe that this study is the first step toward a better understanding of the real‐life outcomes of patients with ML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma

Author

Alonso-Álvarez, Sara, primary, Manni, Martina, additional, Montoto, Silvia, additional, Sarkozy, Clémentine, additional, Morschhauser, Franck, additional, Wondergem, Marielle J., additional, Guarini, Attilio, additional, Magnano, Laura, additional, Alcoceba, Miguel, additional, Chamuleau, Martine, additional, Galimberti, Sara, additional, Gomes da Silva, Maria, additional, Holte, Harald, additional, Zucca, Emanuele, additional, Lockmer, Sandra, additional, Aurer, Igor, additional, Marcheselli, Luigi, additional, Stepanishyna, Yana, additional, Caballero Barrigón, María Dolores, additional, Salles, Gilles, additional, and Federico, Massimo, additional

Published
2021
Full Text
View/download PDF

20. Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Author

Zucca, Emanuele, Ceriani, Luca, Davies, Andrew S., Ciccone, Giovannino, Ricardi, Umberto, Di Rocco, Alice, Kryachok, Iryna, Botto, Barbara, Balzarotti, Monica, Tucci, Alessandra, Zilioli, Vittorio Ruggero, Usai, Sara, Arcaini, Luca, Pennese, Elsa, Dabrowska-Iwanicka, Anna, Ferreri, Andrés José María, Merli, Franceso, Zhao, Wei Li, Hodgson, David, Ionescu, Codruta, Rigacci, Luigi, Cellini, Claudia, Stelitano, Caterina, Volpetti, Stefano, Minoia, Carla, Spina, Michele, Fossa, Alexander, Mikhaeel, George, Cwynarski, Kate, Janikova, Andrea, Stepanishyna, Yana, Jerkeman, Mats, Huettmann, Andreas, da Silva, Maria Gomes, Stevens, Don A., Barrington, Sally F, Małkowski, Bogdan, Metser, Ur, Versari, Annibale, Chauvie, Stephane, Bagni, Oreste, Cozens, Kelly, Perticone, Sonia, Ielmini, Nicoletta, Deantonio, Letizia, Walewski, Jan, Trneny, Marek, Gospodarowicz, Mary, Cavalli, Franco, Johnson, Peter, and Martelli, Maurizio

Published
2023
Full Text
View/download PDF

22. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

Author

Massaro, Fulvio, primary, Stepanishyna, Yana, additional, Manni, Martina, additional, Luminari, Stefano, additional, Galimberti, Sara, additional, Marcheselli, Luigi, additional, Visco, Carlo, additional, Tecchio, Cristina, additional, Stelitano, Caterina, additional, Angrilli, Francesco, additional, Petrini, Mario, additional, Merli, Francesco, additional, and Federico, Massimo, additional

Published
2020
Full Text
View/download PDF

23. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.

Author

Massaro, Fulvio, Stepanishyna, Yana, Manni, Martina, Luminari, Stefano, Galimberti, Sara, Marcheselli, Luigi, Visco, Carlo, Tecchio, Cristina, Stelitano, Caterina, Angrilli, Francesco, Petrini, Mario, Merli, Francesco, and Federico, Massimo

Subjects
*RITUXIMAB, *METHOTREXATE, *CYTARABINE, *STEM cell transplantation, *LYMPHOPROLIFERATIVE disorders, *MANTLE cell lymphoma, *CASTLEMAN'S disease
Abstract

Summary: Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R‐HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R‐CVAD) alternating with high‐dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow‐up of 10·5 years, we reported 10‐year progression‐free and overall survival rates of 35% and 61% respectively, with a 10‐years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD‐AM as a frontline regimen for younger patients (≤65 years). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Interim-PET As a Predictive Factor in Patients with Hodgkin's Lymphoma

Author

Kryachok, Irina, Novosad, Olga, Pastushenko, Ian, Skrypets, Tetiana, Kadnikova, Tetiana, Tytorenko, Iryna, Kushchevyy, Evgen, Ulianchenko, Kateryna, Filonenko, Kateryna, Stepanishyna, Yana, Aleksik, Olena, Kmetyuk, Yaroslav, Karpova, Olga, Mykhalska, Larisa, Kindrakevych, Olga, Pylypenko, Halyna, Lukjanec, Olena, Duma, Viktor, Kozlov, Viktor, Batyuk, Liliya, Ryzhak, Olena, Strembitska, Nataliia, Chikalova, Hanna, Chupryna, Myroslava, Kozlov, Iurii, Novikov, Mykola, Kosinova, Viktoriia, Oliinichenko, Olena, Lola, Olena, Kholodna, Alina, Loza, Olga, Kostiukova, Nina, Tkachenko, Oksana, Karnabeda, Oksana, Stratienko, Viktoriya, Gorbach, Oleksandr, and Danilov, Alexey

Abstract

Introduction.PET-CT is the new standard for staging of patients with Hodgkin Lymphoma (HL). However, it is becoming obvious that the role of PET-CT in assessment of response is not limited to imaging at the end-of-treatment. In recent years the prognostic role of interim PET-CT and attempt to use PET response-adapted therapy has come under evaluation across a number of international studies with promising results. Here we report the results of a multicenter retrospective study of interim PET in HL.

Published
2017
Full Text
View/download PDF

25. Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Author

Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, Balzarotti M, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka A, Ferreri AJ, Merli F, Zhao W, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel G, Jerkeman M, Di Rocco A, Stepanishyna Y, Vitolo U, Santoro A, Re A, Puccini B, Olivieri J, Petrucci L, Barrington SF, Malkowski B, Metser U, Versari A, Chauvie S, Walewski J, Trneny M, Cavalli F, Gospodarowicz M, Johnson PWM, Davies A, and Zucca E

Abstract

Background: The role of consolidation radiotherapy in primary mediastinal B-cell lymphoma (PMBCL) patients is controversial., Methods: The IELSG37 trial, a randomized non-inferiority study, aimed to assess whether irradiation can be omitted in PMBCL patients with complete metabolic response (CMR) after induction immunochemotherapy. Primary endpoint was progression-free survival (PFS) at 30 months post-randomization. Patients with CMR were randomly assigned to observation or consolidation radiotherapy (30 Gy). With a non-inferiority margin of 10% (assuming a 30-month PFS of 85% in both arms), a sample size of 540 patients was planned with 376 expected to be randomized., Results: The observed events were considerably lower than expected, therefore, primary endpoint analysis was conducted when ≥95% of patients were followed for ≥30 months. Of 545 patients enrolled, 268 were in CMR after induction and were randomized to observation (n=132) or radiotherapy (n=136). The 30-month PFS was 96.2% in the observation arm and 98.5% in the radiotherapy arm, with a stratified hazard ratio of 1.47 (95%CI, 0.34 to 6.28) and absolute risk difference of 0.68% (95%CI, -0.97% to 7.46%). The 5-year overall survival was 99% in both arms.Non-randomized patients were managed according to local policies. Radiotherapy was the only treatment in 86% of those with Deauville score (DS) 4 and in 57% of those with DS 5. The 5-year PFS and OS of patients with DS 4 (95.8% and 97.5%, respectively) were not significantly different from those of randomized patients. Patients with DS5 had significantly poorer 5-year PFS and OS (60.3% and 74.6%, respectively)., Conclusions: This study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results